Adipose tissue is now recognized by the scientific community as the most accessible and abundant source of mesenchymal cells with tissue repair potential. A single liposuction procedure can yield native adipose tissue, stromal vascular fraction (SVF), and adipogenic progenitor cells (APCs/ASCs), with documented applications in at least nine distinct clinical indications.
For LipAge partner physicians: cryopreserving adipose tissue at the time of liposuction creates an autologous biological bank for future use upon medical indication in any of these settings — guided by clinical judgment, at the appropriate time.
Clinical/regulatory maturity traffic light: 🟢 Robust clinical evidence · 🟡 Preclinical evidence or case series · 🔴 Experimental
| 🟢 Chronic Wounds | SVF / ASCs. Paracrine effect — VEGF, HGF, TGF-β. Angiogenesis + inflammatory modulation. Phase I/II clinical studies in diabetic and venous ulcers. Perugini & Santin, Biomedicines, 2020. |
| 🟢 Breast Reconstruction and Radiation Injury | Native tissue / SVF. Post-radiation tissue remodeling — neoangiogenesis, replacement of fibrosis with functional tissue. 730 patients (Muntean et al., J Clin Med, 2025). See Issue No. 02. |
| 🟡 Systemic Sclerosis — Hands | SVF / Expanded ASCs. Immunomodulation — reduced fibrotic response. Multiple pilot studies. Del Papa N et al., Stem Cells Transl Med, 2019. |
| 🟡 Broad Tissue Repair | SVF / Nanofat. Multi-signal paracrine activity — support for ECM remodeling, neoangiogenesis, and local cell differentiation. |
| 🟢 Scars, Burns, and Pain | Native tissue / SVF / ASCs. Inhibition of hypertrophic scar fibroblasts via p38/MAPK. Reduced scar contraction. See Issue No. 07. |
| 🟡 Extraintestinal Cutaneous Fistulas | Expanded ASCs. Local immunomodulation — regulation of the inflammatory response in fistulas. Clinical studies in Crohn's fistulas. García-Arranz M et al., Stem Cells Transl Med, 2016. |
| 🟢 Knee Osteoarthritis (MFAT/SVF) | Intra-articular MFAT / SVF / ASCs. Synovial inflammatory modulation, chondrogenesis. Meta-analysis of RCTs (Kim KI et al., Am J Sports Med, 2023) — SVF superior to hyaluronic acid on WOMAC/VAS. |
| 🟡 Neuropathic Pain — Peripheral Nerve | Native tissue / SVF. Neuroprotection — perineural neovascularization, neurotrophic factors (NGF, BDNF). Saffari TM et al., Neural Regen Res, 2022. |
| 🟢 Stress Urinary Incontinence | Autologous ASCs. Urethral sphincter repair under investigation. Phase I/IIa trials: 37.5% objective improvement in men, 50% in women. García-Arranz M et al., Neurourol Urodyn, 2021. |
The overview of indications in this issue provides a direct scientific basis for a central strategic proposition of LipAge: no patient knows, at the time of liposuction, which of these nine indications will be relevant to them in the future.
Liposuction creates a unique collection window: the patient is in the operating room, the tissue is available, and the procedure is already underway. The difference with LipAge is simple: instead of discarding this material, cryopreserve it.
The question for the patient is not 'What will I use it for?', but 'Which of these indications might I need it for in 5, 10, or 15 years?'
Diabetic wounds. Osteoarthritis. Post-oncological reconstruction. Sphincter dysfunction. Radiation sequelae. Scars. Peripheral neuropathy. LipAge is not a product for a single indication — it is a platform for multiple possible indications.
The indications described in this newsletter are documented in indexed scientific literature at the evidence levels indicated. Their clinical use in Brazil is subject to the regulatory standards of ANVISA (Brazil's health regulatory agency) and the classification of each adipose tissue fraction as a healthcare product or procedure.
LIPAGE RULE: The service makes cryopreserved autologous material available for future use upon medical indication, based on the attending physician's clinical judgment. The physician decides when and how to use the material, according to the individual indication and applicable regulatory requirements.
PROHIBITED: promising any specific clinical benefit or presenting LipAge as an intervention for any of these conditions.